Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

UPTAKE - Atendimento Virtual: Hospital Domiciliar Virtual com Monitoramento Remoto para Reduzir Hospitalização em Cuidados Agudos (UPTAKE-VC)

5 de novembro de 2026 atualizado por: University of Calgary

Usando ferramentas digitais e de risco personalizadas para orientar transições após eventos renais agudos - Atendimento virtual: hospital domiciliar virtual com monitoramento remoto para reduzir a hospitalização por cuidados agudos

Method: Randomized Controlled Trial Study Duration: 3 Years Study Centre(s) University of Calgary and University of Alberta Objectives: To fill care gaps by implementing strategies to reduce length of hospital stay, readmission rates, and improve long-term outcomes after Acute Kidney Injury (AKI). Number of Participants: Three Hundred and fifty four (n=354) Diagnosis and Main Inclusion Criteria: Hospitalized adults with AKI at high risk of hospital readmission or death

Study Intervention: Multi-component Digital Health Solutions, including:

  1. Computerized Clinical Decision Support (CDS) and
  2. Virtual Care Delivered through Hospital at Home (VC) Duration of administration: Determined by the Patient's clinical team Reference therapy: Usual Care Statistical Analyses: Descriptive Analysis, Regression

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

  1. Background and Rationale

    Acute kidney injury (AKI) is a common and serious complication in hospitals. A major care gap for survivors of AKI is the fragmentation of care that exists as they transition from the hospital to their home. This contributes to a high risk of adverse long-term outcomes, including prolonged hospitalization, high rates of readmission, cardiovascular events, infections, progression to chronic kidney disease (CKD), kidney failure requiring dialysis, and death.

    To address this challenge, the investigators are implementing multi-component digital health solutions including Computerized Clinical Decision Support (CDS) and Digital Remote Patient Monitoring (dRPM) through Virtual Care (VC) programs in Alberta to reduce length of hospital stay and readmission rates and improve long-term outcomes after AKI.

    Evidence of the effectiveness of the two digital health solutions is available from Alberta and international clinical trials. Our team previously implemented a computerized CDS intervention for AKI risk assessment and prevention and achieved improved AKI prevention and reduced AKI incidence after cardiac procedures across the province. The investigators will use a similar approach to identify high risk patients with AKI and provide recommendations to improve the quality of their care, which is well suited to the evolving digital health infrastructure in Alberta.

    Providing hospital-level care at home through Virtual Care (VC) teams has been shown to reduce mortality and readmission rates. Alberta's VC program have existed in both Edmonton and Calgary since 2018 and have reported lower readmission rates, Emergency Department (ED) visits and use of Emergency Medical Services than observed with usual care. Patients reported that the program helped them regain their independence and function. Alberta's VC programs have implemented dRPM technology, which has been further associated with fewer days in hospital and emergency department visits. Patients reported better quality of care using this technology. The framework for dRPM and complex care planning is already in place in Alberta's Virtual Care programs. The investigators intend to utilize these programs to improve transitions of care through early facilitated discharge and enhanced follow-up of patients with AKI at high risk of hospital readmission, who require frequent monitoring and more intensive care strategies during this vulnerable period of transition in care.

  2. Research Question and Objectives

    • Implement and evaluate a transition of care intervention for patients with AKI.
    • Integrate digital health solutions that can achieve levels of monitoring and care in a patient's own home that are comparable to acute care, while transitioning care to the community setting.
    • Reduce the length of hospital stay and risk of hospital readmission for people with AKI.
    • Improve the long-term outcomes after hospitalization with AKI.
  3. Methods

The investigators will evaluate implementation initially in a Vanguard phase to establish feasibility and acceptability of the intervention, followed by an evaluation of implementation and effectiveness of the intervention in a larger Multicenter Randomized Controlled Trial (RCT). High risk patients with AKI and a predicted risk of readmission or death ≥20% will be identified using a Best Practice Alert (BPA) in Connect Care and participants will be randomized to care with or without virtual monitoring through the VC programs. All patients will receive the same baseline interventions refined in the Vanguard phase, while the intervention arm will additionally receive VC with dRPM following discharge.

High risk patients in the intervention arm will be navigated through the transition of care pathway by a trained nurse navigator. Patients will receive dRPM kits, and biometric data will be automatically uploaded to the web-based monitoring platform and reviewed by the nurse navigator. Patients will receive regular virtual assessments via telephone or videoconferencing (via the tablet) after in-patient discharge. Blood tests will be drawn at home by community paramedics as deemed necessary by the clinical team to assess kidney function and monitor for complications of AKI. Should concerns be identified that warrant in-person assessment, paramedic care teams will be sent for assessment and/or intervention. Upon completion of the intervention patients will be assessed for readiness to move to the subacute arms of the program and return to their primary care provider. If ongoing nephrologist or other specialist care is required, the nurse navigator will ensure appropriate follow up is arranged.

Tipo de estudo

Intervencional

Inscrição (Estimado)

354

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Director
  • Número de telefone: +1 (403) 210. 6730
  • E-mail: cccr@ucalgary.ca

Locais de estudo

    • Alberta
      • Calgary, Alberta, Canadá, T2N 1N4
        • Recrutamento
        • University of Calgary
        • Contato:
        • Investigador principal:
          • Matthew T James, MD PhD FRCPC
      • Edmonton, Alberta, Canadá, T6G 2G3
        • Recrutamento
        • University of Alberta
        • Contato:
        • Investigador principal:
          • Neesh Pannu, MD SM FRCPC

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age ≥ 18 years old.
  • AKI identified in hospital using Kidney Disease Improving Global Outcomes (KDIGO) criteria17.
  • Hospitalization > 48 hours.
  • LACE (L= Length patient Stay in the hospital, A= Acuity of Admission of patient in the hospital, C= Comorbidity and E= Emergency Visit.) Score 12 or higher.
  • Meets all inclusion criteria of Virtual Home Hospital programs of Calgary and Edmonton zones.

Exclusion Criteria:

  • Non-Alberta residents.
  • Resides outside the catchment areas for the Calgary and Edmonton Virtual Home Hospital programs.
  • C1 or C2 goals of care.
  • Hospitalization > 30 days.
  • Will be discharged to long-term care.
  • Kidney failure receiving dialysis.
  • Already admitted in Virtual Home Hospital Program

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Virtual Care

Participants will receive virtual care through Virtual Home Hospital programs in Alberta for their hospital to home transition of care.

Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.

Sem intervenção: Usual Care

Participants will be discharged as per usual care practices from hospital to their home.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
the number of days alive out of hospital
Prazo: Up to 45 days from the date of randomization

the number of days alive out of hospital

Up to 45 days from the date of randomization

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
the time as inpatient in hospital
Prazo: Up to 45 days from the date of randomization

the time as inpatient in hospital

Up to 45 days from the date of randomization
death
Prazo: from the date of randomization up to 45 days, or date of death from any cause, whichever came first,

death records from health administrative data.

from the date of randomization up to 45 days, or date of death from any cause, whichever came first,
hospital readmission
Prazo: Up to 45 days from the date of randomization

hospital readmission records from health administrative data.

Up to 45 days from the date of randomization
Emergency Department visits
Prazo: Up to 45 days from the date of randomization

Emergency Department visit records from health administrative data.

Up to 45 days from the date of randomization
Estimated Glomerular Filtration (eGFR)
Prazo: At 90 days after the date of randomization

eGFR

At 90 days after the date of randomization
Urine Albumin Creatinine Ration (ACR)
Prazo: At 90 days after the date of randomization

ACR laboratory test

At 90 days after the date of randomization
total number of physician visits
Prazo: Up to 45 days from the date of randomization

total number of physician visits

Up to 45 days from the date of randomization
number of physician visits by specialty
Prazo: Up to 45 days from the date of randomization

primary care vs. non-primary care

Up to 45 days from the date of randomization
Changes to medication prescription
Prazo: Up to 45 days from the date of randomization

Changes to medication prescription (including starting, stopping, or dose adjustment) of an Angiotensin-Converting Enzyme Inhibitors (ACEI)/Angiotensin receptor blockers (ARB), diuretic, SGLT2 inhibitor, or NSAID or administration of IV fluid

Up to 45 days from the date of randomization
laboratory testing
Prazo: Up to 45 days from the date of randomization

Number of creatinine/eGFR, electrolytes, and urine protein quantification

Up to 45 days from the date of randomization
patient experience care transition measure
Prazo: At 45 days after the date of randomization

Online Survey

At 45 days after the date of randomization
Euro Qol- 5 Dimension (EQ5D)
Prazo: At 45 days after the date of randomization

Online Survey to assess quality of life mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" to "extreme problems

At 45 days after the date of randomization

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Matthew James, MD, University of Calgary

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de agosto de 2024

Conclusão Primária (Estimado)

30 de junho de 2027

Conclusão do estudo (Estimado)

31 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

29 de julho de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de agosto de 2024

Primeira postagem (Real)

5 de agosto de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever